It’s no exaggeration to say that the past decade has revolutionized how we think about and treat obesity. Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have dominated headlines, enabling significant weight loss at speeds once considered unthinkable. The market for innovative weight loss medications is booming, with pharmaceutical companies investing heavily in hopes of developing the next blockbuster drug.

However, amid this race for market dominance, many experts are questioning whether the amount of weight loss alone is the best measure of these drugs’ usefulness. How can the next generation of obesity treatments meaningfully improve upon the powerful options already available?

Joining The Lancet editors Callam Davidson and Miriam Sabin to discuss this question is Professor Steven Heymsfield from the Pennington Biomedical Research Center. This wide-ranging conversation covers exciting pharmaceutical advances and limitations of these treatments, including the significant disparities in access, and why these breakthroughs may have broader societal implications.

Send us your feedback!

Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancet

Check out all the podcasts from The Lancet Group:
https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancet

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

The sustainability of our existence relies on the health of every human, every animal, and the environment we all share. Published today, "The Lancet One Health Commission: harnessing our interconnectedness for equitable, sustainable, and healthy socioecological systems" highlights challenges like climate change, food security, and antimicrobial resistance to lay out the One Health approach to informing and implementing solutions.

Senior Executive Editor at The Lancet Pam Das is joined by lead Commissioners, Andrea Winkler and John Amuasi, to explain the past, present, and future of the One Health concept.

You can read the Commission here:

https://www.thelancet.com/commissions-do/one-health?dgcid=buzzsprout_tlv_podcast_lancetonehealth25_lancet

Send us your feedback!

Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancet

Check out all the podcasts from The Lancet Group:
https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancet

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Professor Adam Kucharski joins Gavin & Jessamy to discuss the intersection of mathematics, epidemiology, and truth, off the back of his new book, Proof. How do we generate scientific knowledge? How can we communicate uncertainty? What is the impact of social media and artificial intelligence on public trust in science?

Adam also tells us about the importance of public engagement, the nuances of misinformation, the importance of transparency in policy, the future of scientific communications, the need for adaptable definitions of proof, and the value of pragmatic, transparent approaches to decision-making in health and science.

Send us your feedback!

Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancet

Check out all the podcasts from The Lancet Group:
https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancet

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv